These findings confirmed the clinical benefits of mature TLSs in CRC and suggested that the interactions between CD4 + Tfh and BGC cells might differ between early and advanced CRC, potentially influencing the observed variations in TLS formation across disease stages. The gene discussed is CD4; the disease is colorectal carcinoma.